In vitro effects of Mim8 and combined Mim8-bypassing therapy on thrombin generation, thromboelastography and fibrin clot ultrastructure
Mim8 significantly improves TG in vitro in both PPP and PRP from patients with severe HA, with ETP levels comparable to those of FVIII at 100 IU/dL. The TGA can effectively monitor the combined treatment with Mim8 and either rFVIIa or APCC, which is not possible with currently available routine laboratory tests.
Authors
- Christophe Nougier (ORCID: https://orcid.org/0000-0003-0578-242X)
- Jacob Lund (ORCID: https://orcid.org/0000-0001-8627-7382)
- Laurie Josset
- Hamdi Rezigue (ORCID: https://orcid.org/0009-0003-3765-3603)
- G Yesim Dargaud
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Novo Nordisk (Denmark) (DK)
- Communauté urbaine de Lyon (FR)
Publication Details
- Journal
- Thrombosis Research
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1016/j.thromres.2025.109341
- Citations
- 2
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 3.54
Funders
- Novo Nordisk